Pasithea Therapeutics jumped 117% after launching a large equity offering and gaining momentum for its PAS-004 drug, supported by a $1 million ALS Association grant. Strong early-stage data and rising retail chatter fuelled the stocks best day in four years, with shares extending gains after hours.